Open Access Article
Aron H. Blaesi*ab,
Henning Richterc and
Nannaji Sakad
aEnzian Pharmaceutics Blaesi AG, CH-7078 Lenzerheide, Switzerland
bEnzian Pharmaceutics, Inc., Cambridge, MA 02139, USA. E-mail: ablaesi@enzianpharma.com
cDiagnostic Imaging Research Unit (DIRU), Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, CH-8057 Zurich, Switzerland
dDepartment of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
First published on 1st April 2026
Correction for ‘Enhancing the bioavailability of sparingly-soluble drugs by expandable, solid-solution fibrous dosage forms’ by Aron H. Blaesi et al., RSC Pharm., 2026, 3, 88–102, https://doi.org/10.1039/D5PM00195A.
On the left hand side of eqn (6), “r” should be replaced with “z”. The corrected equation is shown below.
![]() | (6) |
The sentence underneath eqn (10) should refer to eqn (10) instead of eqn (9). Eqn (10) and the corrected sentence are given below.
![]() | (10) |
“For the parameter values listed in Appendix B, Md,0 = 200 mg, Dd,df = 4.22 × 10−10 m2 s−1, and H = 9.8 mm, by eqn (10) dmd,r/dt = 50, 30, and 14 mg h−1 after 1, 3, and 5 hours, respectively.”
The sentence underneath eqn (12b) should refer to eqn (12a) instead of eqn (11a). The corrected sentence is given below.
“Rearranging eqn (12a), the drug concentration in gastric fluid at time ti+1 may be written as:”
An independent expert has reviewed these changes and confirmed a correction notice is required. The discussions and conclusions are unaffected by these changes.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2026 |